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Response to Letter to the Editor: ‘Autologous chondrocyte implantation
for the treatment of cartilage lesions; randomized control trials assessed
in a systematic review’Wewant to thank Drs Vasiliadis and Salanti for their letter. First
of all it is most gratifying to see that another, independent group of
investigators shared our notion that a systematic review of autolo-
gous chondrocyte implantation was needed and that they reached
essentially the same conclusion despite using a methodologically
different approach1.
Vasiliadis and Salanti make two important points. First, the
overall quality of the studies published on autologous chondrocyte
implantation is rather poor, which implies a number of concerns
about the validity of their ﬁndings. Also, the amount of information
given on study design andmethods in the included primary studies
was somewhat limited, leading to slightly different interpretations
between the two reviews1. Moreover, assessing items of study
quality is not as clear-cut as it is often assumed, as the letter by
Vance Berger (see below) illustrates.
Secondly, there is substantial overlap between and within
studies. The essential problem is that multiple published papers
draw from the same population, but only some with new study
questions. Vasiliadis and Salanti point out that we had claimed to
include nine studies, but we like to direct their attention to the ﬁrst
paragraph of the results section where we tried to untangle the six
trials vs nine papers situation. Knutsen et al., for example, report
largely the same clinical outcomes at two different time points2
and 5 years, thus we considered this a “two papers out of one trial”
situation. As Vasiliadis and Salanti points out, there was much
dispute whether Horas et al. changed more than the language of
publication between their two publications or actually presented a
(ny) new study question(s) in their second paper2. Saris et al., in
turn, had major change in endpoints when they reported histology
at 18 months, but MRI at 36 months. Does such a change in the
primary outcome qualify this as a new study building on the same
population, or is this also a twopapers outof only one trial situation?
What stands out from all this is, as Vasiliadis and Salanti
point out in their letter, that there is a considerable need for
high-quality studies with systematic, high-quality reporting in1063-4584/$ – see front matter  2010 Osteoarthritis Research Society International. Pu
doi:10.1016/j.joca.2010.07.001the ﬁeld of cartilage repair. However, despite the state of the
“current best evidence” in cartilage repair, it is interesting to see
that two independent systematic reviews1,3, with each possessing
distinctly different methods, arrived at consistent results suggest-
ing a favorable outcome after ACI, after adjusting for potential bias.Conﬂict of interest
None.
References
1. Vasiliadis HS, Wasiak J, Salanti G. Autologous chondrocyte
implantation for the treatment of cartilage lesions of the knee:
a systematic review of randomized studies. Knee Surg Sports
Traumatol Arthrosc 2010 Feb. 2 [Epub ahead of print].
2. Smith GD, Richardson JB, Brittberg M, Erggelet C, Verdonk R,
KnutsenG, et al. Autologous chondrocyte implantationandosteo-
chondral cylinder transplantation in cartilage repair of the knee
joint. J Bone Joint Surg Am 2003 December 1;85(12):2487–8
(U. Horas, D. Pelinkovic, T. Aigner, and R. Schnettler reply).
3. Vavken P, Samartzis D. Effectiveness of autologous chondrocyte
implantation in cartilage repair of the knee: a systematic
review of controlled trials. Osteoarthritis Cartilage 2010 Jun;
18(6):857–63.
P. Vavken
Children’s Hospital Boston, Boston,
United States
Address correspondence and reprint requests to: Patrick Vavken,
Children’s Hospital Boston, Department of Orthopedic Surgery,
300 Longwood Ave, Enders 1016, Boston 02115, United States.
Tel: 1-6179192105; Fax: 1-6177300170.
E-mail address: patrick.vavken@childrens.harvard.edublished by Elsevier Ltd. All rights reserved.
